AngioDynamics Ends FY 2026 Q2 with $41.6M in Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
AngioDynamics ended fiscal 2026 second quarter with $41.6M in cash and cash equivalents, ahead of the company's expectations. It continues to expect to be cash flow positive for the full year FY 2026.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ANGO with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ANGO
Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.010
Low
16.00
Averages
19.33
High
24.00
Current: 10.010
Low
16.00
Averages
19.33
High
24.00
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AngioDynamics (ANGO) Q3 2025 Earnings Transcript
Continue Reading
AngioDynamics (ANGO) Q1 2026 Earnings Transcript
Continue Reading